These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21688481)

  • 21. [Monitoring of calcineurin inhibitors induced-nephrotoxicity].
    Kamar N; Rostaing L
    Nephrol Ther; 2008 Jun; 4 Suppl 1():S13-S17. PubMed ID: 18703392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.
    Esposito C; Foschi A; Parrilla B; Cornacchia F; Fasoli G; Plati AR; De Mauri A; Mazzullo T; Scudellaro R; Dal Canton A
    Transplant Proc; 2004 Apr; 36(3):695-7. PubMed ID: 15110634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
    Chapman JR; Nankivell BJ
    Nephrol Dial Transplant; 2006 Aug; 21(8):2060-3. PubMed ID: 16728428
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunohistochemical markers of renal tubular injury and cyclosporin nephrotoxicity in kidney allograft biopsies.
    García Del Moral R; Navarro N; Montes A; Aguilar D; Aneiros J
    Nephron; 1992; 62(1):121-2. PubMed ID: 1436283
    [No Abstract]   [Full Text] [Related]  

  • 28. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
    Pérez-Rojas J; Blanco JA; Cruz C; Trujillo J; Vaidya VS; Uribe N; Bonventre JV; Gamba G; Bobadilla NA
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F131-9. PubMed ID: 16835406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression of renal disease and renal hypertrophy.
    Hostetter TH
    Annu Rev Physiol; 1995; 57():263-78. PubMed ID: 7778868
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic allograft nephropathy.
    Pietrzyk M; Hoffmann U; Krämer BK
    N Engl J Med; 2004 Mar; 350(12):1254-6; author reply 1254-6. PubMed ID: 15031859
    [No Abstract]   [Full Text] [Related]  

  • 32. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 34. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar?
    Morozumi K; Sugito K; Oda A; Takeuchi O; Fukuda M; Usami T; Oikawa T; Fujinami T; Koyama K; Takeda A; Yoshida A; Haba T; Tominaga Y; Uchida K; Yokoyama I; Takagi H
    Transplant Proc; 1996 Apr; 28(2):1076-8. PubMed ID: 8623232
    [No Abstract]   [Full Text] [Related]  

  • 36. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New strategies to reduce nephrotoxicity.
    Kreis H
    Transplantation; 2001 Dec; 72(12 Suppl):S99-104. PubMed ID: 11833149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet CD61 expression in vascular calcineurin inhibitor toxicity of renal allografts.
    Meehan SM; Baliga R; Poduval R; Chang A; Kadambi PV
    Hum Pathol; 2008 Apr; 39(4):550-6. PubMed ID: 18234279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease.
    Remuzzi A; Mohamed EI
    Exp Nephrol; 1996; 4 Suppl 1():27-33. PubMed ID: 9001894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein.
    Joy MS; Nickeleit V; Hogan SL; Thompson BD; Finn WF
    Pharmacotherapy; 2005 Jun; 25(6):779-89. PubMed ID: 15927895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.